Accrol Group Holdings plc (LON:ACRL), the UK’s leading independent tissue convertor, has announced that, following final settlement with the vendor of Leicester Tissue Company, no sums are due to be paid nor equity issued under the deferred consideration arrangements relating to the acquisition of LTC.
Further details of the acquisition of LTC are contained in the announcement issued by the Company on 2 November 2020 titled “Acquisition and Launch of ABB”.
Dan Wright, Chairman of Accrol Group Holdings, said: “LTC has proven an extremely valuable addition to the Accrol manufacturing footprint. Its operations are now fully integrated within the wider Accrol business, allowing us to accommodate considerable growth and realise significant efficiencies and synergies across the Group.”
